Alexander Reuss
University of Marburg
111 Papers
273 Citations
Alexander Reuss is an academic researcher from University of Marburg. The author has contributed to research in topics: Medicine & Ovarian cancer. The author has an hindex of 30, co-authored 86 publications. Previous affiliations of Alexander Reuss include Charité.
Chat about Author
Papers
A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease
Günther Deuschl,Carmen Schade-Brittinger,Paul Krack,Jens Volkmann,Helmut Schäfer,Kai Bötzel,C. Daniels,Angela Deutschländer,Ulrich Dillmann,Wilhelm Eisner,Doreen Gruber,Wolfgang Hamel,Jan Herzog,Rüdiger Hilker,Stephan Klebe,Manja Kloss,J. Koy,Martin Krause,Andreas Kupsch,Delia Lorenz,Stefan Lorenzl,H. Maximilian Mehdorn,Jean Richard Moringlane,Wolfgang H. Oertel,Marcus O. Pinsker,Heinz Reichmann,Alexander Reuss,Gerd-Helge Schneider,Alfons Schnitzler,Ulrich Steude,Volker Sturm,Lars Timmermann,Volker M. Tronnier,Thomas Trottenberg,Lars Wojtecki,Elisabeth Wolf,Werner Poewe,Jürgen Voges +37 more
TL;DR: In this six-month study of patients under 75 years of age with severe motor complications of Parkinson's disease, neurostimulation of the subthalamic nucleus was more effective than medical management alone.
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine,Felix Hilpert,Béatrice Weber,Alexander Reuss,Andreas Poveda,Gunnar B. Kristensen,Roberto Sorio,Ignace Vergote,Petronella O. Witteveen,Aristotelis Bamias,Deolinda Pereira,Pauline Wimberger,Ana Oaknin,Mansoor Raza Mirza,Philippe Follana,David T. Bollag,Isabelle Ray-Coquard +16 more
TL;DR: Adding bevacizumab to chemotherapy statistically significantly improved PFS and ORR; the OS trend was not significant.
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).
Andreas du Bois,Alexander Reuss,Eric Pujade-Lauraine,Philipp Harter,Isabelle Ray-Coquard,Jacobus Pfisterer +5 more
TL;DR: In this paper, an exploratory analysis was conducted of three prospective randomized trials (AGO-OVAR 3, 5, and 7) investigating platinum-taxane based chemotherapy regimens in advanced ovarian cancer conducted between 1995 and 2002.
1.5K
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
Philipp Harter,Jalid Sehouli,Domenica Lorusso,Alexander Reuss,Ignace Vergote,Christian Marth,Jae Weon Kim,Francesco Raspagliesi,Björn Lampe,Giovanni Aletti,Werner Meier,David Cibula,Alexander Mustea,Sven Mahner,IB Runnebaum,B Schmalfeldt,Alexander Burges,Rainer Kimmig,Giovanni Scambia,Stefano Greggi,Felix Hilpert,Annette Hasenburg,Peter Hillemanns,Giorgio Giorda,Ingo von Leffern,Carmen Schade-Brittinger,Uwe Wagner,Andreas du Bois +27 more
TL;DR: Systematic pelvic and paraaortic lymphadenectomy in patients with advanced ovarian cancer who had undergone intraabdominal macroscopically complete resection and had normal lymph nodes both before and during surgery was not associated with longer overall or progression‐free survival and was associated with a higher incidence of postoperative complications.
Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO
Philipp Harter,Jalid Sehouli,Alexander Reuss,Annette Hasenburg,Giovanni Scambia,David Cibula,Sven Mahner,Ignace Vergote,Alexander Reinthaller,Alexander Burges,Lars Hanker,Martin Pölcher,Christian Kurzeder,Ulrich Canzler,Karl U. Petry,Andreas Obermair,Edgar Petru,Edgar Petru,Barbara Schmalfeldt,Domenica Lorusso,Andreas du Bois +20 more
TL;DR: This score is the first prospectively validated instrument to positively predict surgical outcome in recurrent ovarian cancer and will be enrolled in the recently started randomized prospective DESKTOP III trial investigating the role of surgery in recurrent platinum-sensitive ovarian cancer.
278